Podcasts about biotech

Raman Sehgal has made a career out of putting his energy— and he's got a lot of it— into building biotech outsourcing companies and the people who make them run. After years spent supporting several from within, he launched ramarketing, a firm dedicated to helping CROs, CDMOs,  CPOs, and other providers to the biotech ecosystem build their businesses, in 2009. He's also an international best-selling author (The Floundering Founder), co-founder of life sciences recruitment firm Lead Candidate,  and founder & host of the Molecule to Market podcast. On this week's episode of the Business of Biotech, Raman brings us his unique and multifaceted perspectives on the biopharma outsourcing space, the bear biotech markets, and how both are impacting the work of early- and clinical-stage biopharma leaders. 

The natural and organic cosmetics world loves sourcing the purest, sustainable plant-based ingredients that are ethically picked, plucked, farmed and harvested, and processed with as little artifice as possible. On this podcast, we have covered a raft of natural ingredient sourcing and formulation concepts from wild-harvesting and biodynamic farming to blue, waterless and upcycled beauty. All of these topics, we have assessed through the lens of sustainability. It is worth reiterating and remembering this as we tackle the topic of this episode of Green Beauty Conversations - biotech beauty. The next most potent, active botanical is possibly being engineered from plant stem cells using biotech right now, as a breakthrough natural cosmetic ingredient. But does the sound of lab-grown plant actives in your cosmetics excite you or worry you? Is it too futuristic or something you'd adopt willingly right now? How receptive would you be to using biotech-based ingredients if your ideal of natural organic cosmetic ingredients is their farming or wild harvesting from forests and fields? The truth is that biotech beauty is happening now, and is gaining momentum - in part, as an answer to some of the key sustainability issues surrounding the farming of crops as cosmetic ingredients.  To give us insights into the world of biotech beauty, Formula Botanica CEO and podcast host Lorraine Dallmeier, herself a biologist and chartered environmentalist, talks to Dr Barbara Paldus of Codex Beauty, a firm pioneering biotech cosmetic formulation. Listen in to this eye-opener on biotech which, given current climate change predictions, could be the new normal for sourcing natural, and even organic, cosmetic ingredients sooner than you think.

In der Rubrik “Investments & Exits” begrüßen wir heute Amanda Birkenholz, Investment Managerin bei UVC Partners. Amanda hat die Finanzierungsrunde von Econic und SecondCircle analysiert: Das in Kopenhagen ansässige Startup SecondCircle hat in einer Pre-Seed-Finanzierungsrunde 1,2 Million Euro eingesammelt. SecondCircle will mithilfe von synthetischer Biologie industrielle Kohlenstoffemissionen aus Emissionen absondern. Die Absonderungen werden dann von Bakterien zu neuen Chemikalien und Materialien umgewandelt, welche wiederum an die Industrie zurückverkauft werden können. Angeführt wird die Finanzierungsrunde vom Berliner Frühphaseninvestor Atlantic Labs. SecondCircle ist aus dem Biosustain NNF Center for Biosustainability an der Dänischen Technischen Universität hervorgegangen. Das 2020 gegründete Unternehmen mit Sitz in Kopenhagen wird von dem Gründerteam Alex Toftgaard Nielsen, Stephanie Redl und Torbjørn Ølshøj Jensen geleitet. Als Teil eines Konsortiums, das Mittel aus dem EU-Forschungs- und Innovationsprogramm Horizont 2020 erhalten hat, konnte sich das BioTech bereits 2020 einen EU-Zuschuss in Höhe von 43 Millionen Euro sichern. Das in London ansässige Startup Econic Technologies, das Katalysatoren und Verfahren für die Herstellung von Polymeren aus Kohlendioxid entwickelt, gab am Dienstag bekannt, dass es in einer zweiten Serie D 10,4 Millionen Pfund (etwa 12,3 Millionen Euro) erhalten hat. Die Finanzierungsrunde wird von OGCI Climate Investments und Capricorn Sustainable Chemistry Fund angeführt. An der Runde beteiligen sich außerdem CM Ventures, GC Ventures und ING Sustainable Investments. Das 2011 von Charlotte Williams gegründete DeepTech Econic will die frischen finanziellen Mittel für die Kommerzialisierung seiner Katalysator- und Prozesstechnologie verwenden, mit der CO2 für die Herstellung von Polymeren genutzt werden kann.

In der heutigen Folge „Alles auf Aktien“ sprechen der Finanzjournalist Holger Zschäpitz und AAA-Friend Christoph Ellinger über aphrodisierende Inflationszahlen, neue Kursfantasie bei Biotech und eine Rallye bei Jumia. Außerdem geht es um Diseny, Netflix, iShares Global Clean (WKN: A0MM0S), Vestas, Nordex, Siemens Energy, Plug Power, Invitae, Invesco NASDAQ Biotech (WKN: A12CCJ), The Trade Desk, Riot Blockchain, Marathon, Geberit, Credit Suisse, Bâloise, Lonza, iShares MSCI Switzerland ETF (WKN: 901550), Lyxor DJ Switzerland Titans 30 (WKN: ETF030), Xtrackers Switzerland UCITS ETF (WKN: DBX1SM), iShares SMI® ETF (WKN: 935568). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Dr. Ying Huang currently serves as Chief Executive Officer of Legend Biotech. He sits on the Board of Directors of Legend, as well as Quanta Therapeutics. Dr. Huang brings over 9 years of experience in research and development at major multi-national pharmaceutical companies and 12 years of experience as a biotechnology analyst on Wall Street. Dr. Huang was a Managing Director and Head of Biotech Equity Research at Bank of America Merrill Lynch where he led a team of analysts covering more than 30 biotechnology companies that encompass a wide range of therapeutic areas. His knowledge and expertise have been recognized by the Institutional Investor survey as a top ranked biotechnology analyst on Wall Street. Dr. Huang previously worked at Wachovia, Credit Suisse, Gleacher and Barclays before joining Bank of America Merrill Lynch. Besides providing investment research to investors, Dr. Huang and his team conducted due diligence for numerous successful initial public offerings (IPOs) and follow-on offerings in the biotechnology sector. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is the co-author of multiple patents and peer reviewed publications. Dr. Huang received his Doctor of Philosophy in Bio-organic Chemistry from Columbia University. He also studied in the Special Class for the Gifted Young at the University of Science and Technology of China and Columbia Business School.

Alex Guillen and Joe Lynch discuss tracking medical shipments. Alex is the Director of Sales, Life Science and Pharma Europe at Tive, the leading provider of real-time supply chain visibility insights that help logistics professionals actively manage their in-transit shipments' location and condition. About Alex Guillen Alex Guillen is an established executive with a proven record in global business and market development, with well-rounded experience in multicultural sales management and brand building. Alex has extensive experience and expertise in cold chain; as Director of Sales, Life Science and Pharma at Tive, Alex leads sales and business development within the company's rapid-growth Life Science division. Previously, Guillen served as a Board Member and leader of Corporate Strategy at SWITRACE S.A, a developer of temperature and humidity data loggers compliant to the Pharma and Biotech industries. Alex's extensive experience also includes serving as Global Cold Chain Director of Fisher Clinical Services, CEO of Escort Cold Chain Solutions SA, and Director for Commercial Operations for Novartis Vaccines. About Tive Tive is a leading provider of real-time supply chain visibility insights that help logistics professionals actively manage their in-transit shipments' location and condition. With Tive, shippers and logistics service providers (LSP) eliminate preventable delays, damage, and shipment failures. Tive‘s solution provides data generated by its industry-leading trackers allowing clients to actively optimize their shipments, improve their customers' experience, and unlock supply chain insights in an actionable real-time manner. Key Takeaways: Tracking Medical Shipments Alex Guillen is the Director of Sales, Life Science and Pharma Europe for Tive, which provides in-transit visibility solutions that help shipping and logistics professionals manage their shipments and eliminate preventable delays and damage. In the podcast interview, Joe and Alex discuss the critical importance of tracking medical shipments, including: Commercial pharmaceuticals Clinical pharmaceuticals Medical cold chain Cryogenic Organ transplants The bar is higher for medical and pharmaceutical shipments because a shipment that is late or out of temperature range could cause loss of life.The Tive Tracker is about the size of a deck of cards and it captures and transmits shipment data in real time with unprecedented accuracy. The Tracker provide real time alerts that enable shippers and their 3PL partners to respond and recover the shipment in the case of temperature breech, tampering, shock, damage, theft, and a variety of other factors. Tive enables shippers and their carrier partners to move from reactive to proactive, which is so important when transporting medical/pharma shipments. Tive provides flexible, scalable solutions bringing end-to-end visibility to supply chain professionals. In additional to medical and pharma, Tive provides solutions for the following supply chain problem areas: Location Tracking for High-Value Goods Chemicals Condition Monitoring Handling Damage Monitoring Damage Alerts for Electronics Shipments Port Delays Environmental Monitoring for Perishables Equipment Delivery Monitoring Automotive Supply Chain Optimization Learn More About Tracking Medical Shipments Alex's LinkedIn Tive LinkedIn Tive website The Tive Story with Krenar Komoni Every Shipment Matters with Jim Waters - YouTube Tive Solo 5G Pharma Tracker Tive Solo 5G Pharma Non-Lithium Tracker The Logistics of Logistics Podcast If you enjoy the podcast, please leave a positive review, subscribe, and share it with your friends and colleagues. The Logistics of Logistics Podcast: Google, Apple, Castbox, Spotify, Stitcher, PlayerFM, Tunein, Podbean, Owltail, Libsyn, Overcast Check out The Logistics of Logistics on Youtube

This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 4 --- 'Using a Gut Model to Predict Which Antibiotics Are Associated with CDI and Which Ones Best Treat CDI' Mark Wilcox, MD, FRCPath (Speaker) Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology, Leeds Teaching Hospitals --- Microbiome Therapeutics in 2021: Almost there for C difficile! Sahil Khanna, MBBS MS (Speaker) Professor of Medicine in the Division of Gastroenterology and Hepatology,, Mayo Clinic --- We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.

Vaxxinity CEO Mei Mei Hu, J.D. leads a company with some lofty ambitions. The democratization of healthcare, interplanetary colonization, and development of accessible therapeutic vaccines to serve and enable both. Those big-picture visions have helped the company establish itself as a pioneer of the "third biologics revolution." On this week's Business of Biotech podcast, Mei Mei joins me to share Vaxxinity's strategy, what "democratization" and "revolution" really mean, why traditional vaccines and biologic therapies are converging to form the "third biologic revolution," and a whole lot more. 

But the Northpond Ventures director is at the center of biotech. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sign Up For a WeBull Stock Market Trading Account Instagram @camboni11 and @kennycolin23 and @wincreaseteam Twitter @camboni11 and @kenndrickcolin and @wincreaseteam In this episode of Marathon Money, we talk about biotech stocks, monkey pox, crypto and more. MarathonMoneyPlus.com

BioTech Pest Management releases information on how its new The New Biotech Pest Management System service will change things in the Pest Control Management space for the better. Further information can be found at https://biotechpros.com/. (https://biotechpros.com/.)

Tim Hayward takes a journey into the world of fungi. There's a global wave of interest in the potential uses of fungi right now - and businesses are catching on and playing their part. Tim starts at the Fungarium in Kew Gardens, the world's biggest collection of dried fungal specimens, guided by collections curator Lee Davies. He then heads to a forest in Finland, where chief executive Eric Puro and lab manager Joette Crosier walk him through the setup at Kääpä Biotech - one of a new breed of fungally-focussed companies with big ambitions rooted in a passion for mushrooms and mycelium. Then he talks with Albert Garcia-Romeu, an assistant professor of psychiatry and behavioural sciences at the Johns Hopkins University School of Medicine. Albert is part of a research team looking at the fungally-derived compound psilocybin - about which there's a huge amount of interest relating to its therapeutic potential. Presenter: Tim Hayward Producer : Richard Ward. Image: Shiitake (Lentinula edodes) mushrooms being cultivated at Kääpä Mushrooms, Karjalohja, Finland. Used with permission. Tim's three-part series about fungi, ‘Fungi: The New Frontier', is available now on BBC Sounds.

This week's podcast guests are Laura Fletcher, head of business development and strategic partnerships at Deep Science Ventures; Matthias Steger, CEO of Endogena Therapeutics; Rodolphe Besserve, CEO, and Georges Rawadi, chief of biotech studio development, at eureKARE; and Biotech Growth Trust portfolio manager, Geoff Hsu.News: 02:30Endogena Therapeutics 5:10eureKARE 21:00Deep Science Ventures 33:46Biotech Growth Trust 47:44Endogena Therapeutics Inc. has announced the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP).RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of vision, for which there is currently no treatment for most patients. It is a leading cause of inherited blindness, with an estimated 1.5 million people worldwide presently affected.eureKARE, an investment company focused on financing and building next generation biotech companies in the fields of synthetic biology, has launched its first synthetic biology studio in Belgium. eureKARE is developing a pan-European biotech studio network covering several areas where synthetic biology can create solutions and high market value products.The synthetic biology studios will focus on biomedical and other thematic applications in different European innovation hotspots. The strategy is based on identifying, selecting, and nurturing high-quality European science. The venture builder Deep Science Ventures (DSV) has expanded an existing alliance with Cancer Research UK's innovation-focused arm Cancer Research Horizons, with the mission to establish new oncology startups in the U.K.Just months after Cancer Research UK (CRUK) established its industry-orientated division Cancer Research Horizons, the research charity has doubled down on a collaboration with DSV, a U.K. venture builder operating in a range of sectors including biotech, agriculture and computation. According to the latest agreement, the partners will co-found startups working in up to 10 areas of oncology, such as improving the number of patients that can benefit from immuno-oncology treatments.The Biotech Growth Trust PLC, based in the UK, seeks capital appreciation through investment in the worldwide biotech industry. It invests in a diversified portfolio of shares and related securities in companies on a worldwide basis.Its portfolio is operated by U.S.-headquartered OrbiMed Capital LLC. Following the strong results of the previous year, the company's NAV (net asset value) per share total return dropped by 33.8%, compared to a 55.1% increase in 2021, and the share price total return was down 37.0%. However, ​​overall, since OrbiMed's appointment in 2005, and to the year end, The Biotech Growth Trust's NAV has increased by 861.6% or 14.3% per annum.In its annual report, the portfolio manager stated the company remains confident that there are a number of potential catalysts that could lead to a recovery in the biotechnology sector this year and into the future, and their overall investment strategy remains unchanged.

A.J. LoiaconoAJ is a successful entrepreneur, with 20 years of experience in pharmacy benefits and software development. As the CEO of Capital Rx, his mission is to change the way pharmacy benefits are priced and administrated in the US. Prior to Capital Rx, AJ was a co-founder of Truveris, where he served for eight years as CEO, Chief Innovation Officer, and Board Member, leading the company to record growth (Deloitte FAST 500 and Crain's Fast50).  Prior to Truveris, AJ co-founded SMS Partners, a joint venture with Realogy (RLGY), and in 2010 exited the partnership with a buyout. In his first venture, AJ started Victrix, a pharmaceutical supply chain software consultancy, and successfully sold the company to Chrysalis Solutions in 2007. John Marchica, CEO, Darwin Research GroupJohn Marchica is a veteran health care strategist and CEO of Darwin Research Group. He is leading ongoing, in-depth research initiatives on integrated health systems, accountable care organizations, and value-based care models. He is a faculty associate in the W.P. Carey School of Business and the graduate College of Health Solutions at Arizona State University.John did his undergraduate work in economics at Knox College, has an MBA and M.A. in public policy from the University of Chicago, and completed his Ph.D. coursework at The Dartmouth Institute. He is an active member of the American College of Healthcare Executives and is pursuing certification as a Fellow. About Darwin Research GroupDarwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin's client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

Riley Jarvis joins Alex Burket on the Rise to the Challenge Podcast. Riley has had his challenge with health and was curious of a way to overcome those challenges and found how sleep could help with his Crohn's. He talks about the journey and how it gave him the inspiration to start his own company called "The Sleep Consultant". We talk about how these changes has given him more to want to accomplish and what is next for him. We talk about so much more on the Rise to the Challenge Podcast.  Check out the links below to learn more about Riley Jarvis:  - Linkedin: Riley Jarvis - Facebook: https://www.facebook.com/riley.jarvis.3

Michele Oshman is Vice President of External Affairs of BIO, and the Executive Director of BIO's Council of State Bioscience Associations (CSBA), advancing public policies that support the bioscience industry in partnership with their state-based member associations.Before joining BIO in 2020, Michele had a successful 18-year career at Eli Lilly and Company, where she led their federal advocacy. She is a neuroscience researcher working both in clinical development and corporate leadership roles. Uncommon for people working in public policy, Michele earned a Six Sigma Black Belt in statistics in 2005 and is a closeted quant!This podcast discusses the multitude of challenges facing the US biopharma sector, including proposed changes to the accelerated approval pathway and the broader issues of affordability related to out of pocket costs in Medicare Part D. Michele Oshman outlines the vital role state associations play in both advancing medical innovations and relationships with local and state governments to ensure that patients have access to needed new medicines.See omnystudio.com/listener for privacy information.

On this episode of MKT Call, Guy Adami and Dan Nathan are joined by Tom Sosnoff of tastytrade and Carter Worth of Worth Charting to discuss: The yield curve inversion deepening OPEC+ agreeing to a modest increase in oil production Two fintech stocks are surging (PayPal, Robinhood) Groups of stocks that may be bottoming (Biotech, Software, Retail) Revisiting Carter's CAT & AMD calls ---- Watch MKT Call at 1pm M-TH on YouTube Sign up for our emails ---- MKT Call is brought to you by our presenting sponsors FactSet, tastytrade, and is powered by OpenExchange. ---- Follow us on Twitter @MKTCall Follow Dan Nathan @RiskReversal on Twitter Follow @GuyAdami on Twitter Follow @CarterBWorth on Twitter Follow us on Instagram @RiskReversalMedia Like us on Facebook  @RiskReversal Watch all of our videos on YouTube

On this episode of MKT Call, Guy Adami and Dan Nathan are joined by Tom Sosnoff of tastytrade and Carter Worth of Worth Charting to discuss: The yield curve inversion deepening OPEC+ agreeing to a modest increase in oil production Two fintech stocks are surging (PayPal, Robinhood) Groups of stocks that may be bottoming (Biotech, Software, Retail) Revisiting Carter's CAT & AMD calls ---- Watch MKT Call at 1pm M-TH on YouTube Sign up for our emails ---- MKT Call is brought to you by our presenting sponsors FactSet, tastytrade, and is powered by OpenExchange. ---- Follow us on Twitter @MKTCall Follow Dan Nathan @RiskReversal on Twitter Follow @GuyAdami on Twitter Follow @CarterBWorth on Twitter Follow us on Instagram @RiskReversalMedia Like us on Facebook  @RiskReversal Watch all of our videos on YouTube

Enochian Biosciences co-founder Serhat Gumrukcu was working to build a name for himself in biotech. But earlier this year, he was arrested in a purported plot to kill an associate. WSJ's Joseph Walker tells the story of Gumrukcu's rise and what prosecutors allege happened.Further Reading: -Biotech Wizard Left a Trail of Fraud – Prosecutors Allege it Ended in Murder  Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Kathrin Meyer from the Center for Gene Therapy at Nationwide Children's Hospital joins me to discuss the current state of gene therapy research - where we are now, and how far we have left to go.

This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 3 Update on the Development of Gut Microbiome Protectors from Antibiotic-Induced Dysbiosis. Florence Sejourne (Speaker) CEO, DA VOLTERRA --- “Safety and Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent Clostridioides difficile Infection: A Data Summary From Five Prospective Studies” Beth Guthmueller (Speaker) Rebiotix, a Ferring Company --- ‘CP101, an Investigational Orally Administered Microbiome Therapeutic Designed to Prevent Recurrent CDI' Shrish Budree (Speaker) Medical Director, Head of Clinical Microbiome Science, Finch Therapeutics --- We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.

As biotech capital markets continue to restrict access to funding for emerging biopharmas, you might be surprised by how many federal dollars get left on the negotiating table.  To that end, James Thomas Coates, Ph.D. and his team at Decisive Point have carved out a niche in the venture capital space. The firm specializes in helping biotech startups realize direct routes to millions of dollars in federal funding from a host of not-so-intuitive federal institutions—NASA, and the US Navy, Air Force, and Army, for instance—and helping them optimize funding from more obvious federal agencies such as DARPA and the NIH. On this episode of the Business of Biotech, Dr. Coates shares strategies and resources for tapping into biopharma capital that's ripe for the taking.

Vance sits down for an As the Crowe flies episode to request 2 things from our listeners:1) Ideas for a mural he hopes to have commissioned for his second daughter, Autumn2) A new pattern language that better captures ideas surrounding long term thinking. To view Vance's first mural for Violet: https://www.vancecrowe.com/violets-muralJoin the Articulate Ventures Network | https://network.articulate.ventures/ —We are a patchwork of thinkers that want to articulate ideas in a forum where they can be respectfully challenged, improved and celebrated so that we can explore complex subjects, learn from those we disagree with and achieve our personal & professional goals.Book a Legacy Interview | https://legacyinterviews.com/ —A Legacy Interview is a two-hour recorded interview with you and a host that can be watched now and viewed in the future. It is a recording of what you experienced, the lessons you learned and the family values you want passed down. We will interview you or a loved one, capturing the sound of their voice, wisdom and a sense of who they are. These recorded conversations will be private, reserved only for the people that you want to share it with.Contact Vance for a Talk | https://www.vancecrowe.com/ —Vance delivers speeches that reveal important aspects of human communication.  Audiences are entertained, engaged, and leave feeling empowered to change something about the way they are communicating.  Vance tells stories about his own experiences, discusses theories in ways that make them relatable and highlights interesting people, books, and media that the audience can learn even more from. Join the #ATCF Book Club | https://www.vancecrowe.com/book-club

In this episode of the Life Science Success podcast I interviewed Stephanie Wisner.  We discussed Co-Founding Centivax and her new book Building Backwards to Biotech: the Power of Entrepreneurship to Drive Cutting-Edge Science to Market.

This week's podcast has two parts. In the first section University of Idaho lactation specialist Dr. Shelley McGuire discusses the recent paper that claims to have found the herbicide glyphosate in breast milk. In the second half Gabe Ignetti from the Ecomodernist Society of North America discusses an environmental movement that embraces science, including biotechnology and nuclear power. 

0:10 - A look at the positive week for markets. Plus, a discussion about housing affordability and challenges for low income earners.12:00 - Corey Adams of Robert Half provides results from a recent jobs survey conducted. 32:25 - Paul LaMonica of CNNBusiness

Innovation without the right outcomes is a recipe for failure for both the project and the business. This simple notion seems obvious, yet countless companies get it wrong from the start, never realizing the missed opportunities for winning products with sustainable value! As a result, mediocre products go out the door to customers every day. In the worst cases, medical device companies have invested 6 to 10 years in a product's development, only to find out that it was the wrong product!   So, how do we remedy this issue? Our recent guest, Tony Ulwick might just have the answer! Tony is the pioneer of Jobs-to-be-Done Theory, the inventor of the Outcome-Driven Innovation® (ODI) process, and the founder of strategy and innovation consulting firm Strategyn. Tony has applied his ODI process at some of the world's leading companies and across nearly all industries to inform breakthrough innovations—achieving a success rate that is 5 times better than the industry average. Philip Kotler calls Tony “the Deming of innovation” and credits him with bringing predictability to innovation. Published in Harvard Business Review and MIT Sloan Management Review, Tony is also the author of best sellers What Customers Want and JOBS TO BE DONE: Theory to Practice

Biotech investor, scientist and author Peter Kolchinsky, Ph.D. joins the show with our Founder and Chairman, Jim Weiss, to discuss what the passing of the Prescription Drug Pricing Reform bill would mean for our industry.

In this episode we are talking to Prof Eric Topol. Eric is a cardiologist by training, a basic scientist in the areas of personalized genomic medicine at the interface between genetics and digital health and is the author of the leading textbook in interventional cardiology in addition to authoring books on AI in medicine. He is the founder and director of the Scripps Research Translational Institute, a professor of molecular medicine at the scripps research institute and a snr consultant at the division of cardiovascular diseases at Scripps Clinic in La Jolla CA. Finally, he is editor in chief of Medscape and theheart.orgSince the COVID pandemic hit Eric has been an outspoken advocate of basic research and optimized paths for COVID drug discovery and development. He has written numerous pieces on COVID and our response to the pandemic in addition to calling out and correcting mis and dis information. His most recent piece, an editorial in the LA Times, continues to draw attention to the low vaccination and booster rates here in the US.Today we discuss the evolution of COVID virus and the most recent BA5 variant. The data continues to be sobering with the increased emergence and dominance of new variants. Eric highlights the importance of the vaccine, boosters and the need to develop a universal vaccine to tackle this pandemic. We also discuss Paxlovid and the rebound that is being observed in around 20% of patients. Finally we touch on the issue regarding disinformation around scientific discoveries in todays world and the need to build systems to actively call this out and quickly correct before it becomes “fact”.To lighten the mood, or so I thought,  at the end we turn to AI and its role in our health system. Touching on some key considerations around AI consciousness that has been in the news of late.

Dr. George Church is a Professor of Genetics at Harvard Medical School and a co-founder of multiple biotech companies. In this wide-ranging interview, he speaks about his work on de-extinction, his vision of a future without age-related illness, and his AI-powered startups.If you like what you hear, let a friend know, subscribe wherever you get your podcasts, and connect with us on Twitter @AIHealthPodcast.

Among the more prevalent genetic conditions, Duchenne muscular dystrophy  affects an estimated one in 3,500 male births worldwide.  It's caused by mutations of the DMD gene, which  regulates the production of a protein called dystrophin. Approved DMD treatments haven't demonstrated strong clinical outcomes, but James McArthur, Ph.D. and his team at PepGen are seeking to change that with a pipeline of disease-modifying peptide-conjugated oligonucleotide candidates derived from the company's Enhanced Delivery Oligonucleotide platform. The Business of Biotech caught up with Dr. McArthur at PepGen's Cambridge headquarters to learn more. Catch up on more gene therapy development advances on bioprocessonline.com.

Thomas Stoeger is a scientist who spends his time looking for promising avenues of research in human health that are currently unexplored. Vance and Thomas discuss how he uses technology to assist him in this, identifying novel avenues for aging and Alzheimer's research and how to think creatively when doing research. Thomas's Page at Northwestern University: https://amaral.northwestern.edu/people/stoeger/Join the Articulate Ventures Network | https://network.articulate.ventures/ —We are a patchwork of thinkers that want to articulate ideas in a forum where they can be respectfully challenged, improved and celebrated so that we can explore complex subjects, learn from those we disagree with and achieve our personal & professional goals.Book a Legacy Interview | https://legacyinterviews.com/ —A Legacy Interview is a two-hour recorded interview with you and a host that can be watched now and viewed in the future. It is a recording of what you experienced, the lessons you learned and the family values you want passed down. We will interview you or a loved one, capturing the sound of their voice, wisdom and a sense of who they are. These recorded conversations will be private, reserved only for the people that you want to share it with.Contact Vance for a Talk | https://www.vancecrowe.com/ —Vance delivers speeches that reveal important aspects of human communication.  Audiences are entertained, engaged, and leave feeling empowered to change something about the way they are communicating.  Vance tells stories about his own experiences, discusses theories in ways that make them relatable and highlights interesting people, books, and media that the audience can learn even more from. Join the #ATCF Book Club | https://www.vancecrowe.com/book-club

Amy has always been drawn to growth and expansion and knew that she could support and serve even more people through investing in multifamily real estate. Her skillset, heart-set, and mindset were a perfect fit for real estate and she is now, providing clean, safe, affordable housing to working-class families. [00:00 - 05:58]Opening Segement Amy Sylvis, founder, and principal of Sylvis capital, a real estate firm that invests in large multi-family properties and emerging markets Amy discusses her journey starting out in Clarksville, Tennessee and acquiring properties in Augusta, Georgia; Decatur, Alabama; and Evansville, Indiana. Amy says that one key to success has been partnering with other professionals in the real estate industry and managing properties effectively. [05:58 - 11:40] Evansville is a great market due to its growing economy and strong infrastructure investments by the state government. The construction of a new bridge between Indiana and Kentucky will make rail lines more accessible. Amy created a massive spreadsheet and let her VA populate it looking for trends that would Help them focus on their growing market. Amy has an MBA and a Background in Biotech where data analysis was a part of her work. She said that understanding numbers and how they change over time are good to stay ahead. [11:40 - 17:05] A Miracle Medication Came to The Market that has greatly improved Amy's health. Amy discusses how having a setback in life can be difficult, but that it is important to have hope and faith. Amy shares that, after going through a debilitating disease, her personal health journey has been a gift in that it has given her a new perspective on anything is possible. She emphasizes the importance of mitigating risk when it comes to real estate investments, citing the potential for a recession and interest rates rising as potential risks. She also recommends market research as a way to hedge against potential risks.   [17:05 - 18:09] Closing Segment Reach out to Amy Sylvis Links Below Final Words   Tweetable Quotes “The true gift of this perspective. I knew from a very young age how precious life was and that tomorrow wasn't guaranteed. So it was up to me to really take advantage and live life to the fullest and really led me to this career because I wasn't sure how long or if at all, I could trade my time for money.” - Amy Sylvis     ----------------------------------------------------------------------------- Connect with Amy Sylvis by emailing her at reachout@silviscapital.com or  visiting sylviscapital.com         Connect with me:   Facebook   LinkedIn   Like, subscribe, and leave us a review on Apple Podcasts, Spotify, Google Podcasts, or whatever platform you listen on. Thank you for tuning in!   Email me → sam@brickeninvestmentgroup.com Want to read the full show notes of the episode? Check it out below: [00:00:00] Amy Sylvis: truly understanding where numbers are and how they change over time and being able to just track them and synthesize, Hey, is this getting better or worse? Is this a trend? Is this a blip on the radar? I humbly present to you that it's a bit simpler than maybe it sounds, I think the hardest part is just, compiling the data. [00:00:17]  [00:00:29] Sam Wilson: Amy Silvis is the founder and principal of Sylvis capital a real estate firm that invests in large multi-family properties and emerging markets throughout the United States. Amy, welcome to the show.  [00:00:40] Amy Sylvis: Thank you so much for having me, Sam. What  [00:00:41] Sam Wilson: a pleasure's mind. There are three questions. I ask every guest who comes in the show in 90 seconds or less. [00:00:45] Sam Wilson: Where did you start? Where are you now? How did you get.  [00:00:48] Amy Sylvis: Sure. So started with my first property in Clarksville, Tennessee. Yes. And what, how did I get there? It was a 10-year-long journey of trial and error and some personal medical issues and all sorts of interesting bumps in the road, but it is a story of the persistence never giving up, and making sure I followed my calling. [00:01:08] Sam Wilson: That is incredible. Now you're based in Los Angeles, right? Yes. So I mean, Clarksville, Tennessee, while for those of you that don't know, it's kind of a submarket almost of Nashville, correct? Clark Clarksville is north and west of Nashville. IFM not mistaken. Yep. how in the world did you end up buying a property in Clarksville? [00:01:26] Sam Wilson: This is now a decade.  [00:01:27] Amy Sylvis: No. A couple of years ago. Okay. A couple of years ago. Yeah. Okay. Yes. Yeah. It took me 10 years to get into this space. I've been in this space for a couple of years now. Yes. so thankfully I'm not crazy enough to buy in California learned that lesson. I live here because of my family, but, right control and. [00:01:42] Amy Sylvis: Eviction moratoriums that are still in place two and a half years post COVID. I am not interested in buying in, the state that I call home. Right. Instead, I'm a big market research guru. Endlessly studying markets saw that there was mass migration into the greater Nashville MSA. I knew that, although there was a ton of institutional competition in the main city going an hour Northwest, as you said of this incredible city with great economic growth, job announcements, and people moving, it was such a great space to be in my journey. [00:02:14] Sam Wilson: Right. And if you did that two years ago, I mean, gosh, that's Tennessees had just nothing but influx. Of residents, even, or ever since then, so that's absolutely fantastic. What do you feel like? So, so, so you bought a property in Clarksville. Where else have you acquired since  [00:02:29] Amy Sylvis: then? [00:02:30] Amy Sylvis: Yes. So we also own in Augusta, Georgia. As a GP owned in Evansville, Indiana, right across the border from Kentucky. Yes. And Decatur, Alabama, just outside of Huntsville.  [00:02:45] Sam Wilson: Yeah. Well, Huntsville's another one of those markets. I mean, not actually too far from it's just straight down 65. From, ex Clarksville is 24, but then 24 to 65 and still is not a far jump from Clarksville then down to Decatur, Alabama. [00:02:59] Sam Wilson: So that's really interesting. How were you able, I guess you, in a couple of years time to acquire so many assets.  [00:03:05] Amy Sylvis: Partnership. I am a self-admitted only child's type a personality that loves to, be self-reliant. And if something needs to be done, gosh, darned, I'm gonna go out and get it right. [00:03:15] Amy Sylvis: Or do it. But, I had great mentorship and realize that I can go further, faster. By partnering with other folks in this space. So, amazing partnerships with people that live in the Southeast and great property management is the recipe to get that going.  [00:03:30] Sam Wilson: Wow. Yeah. Good property management. [00:03:32] Sam Wilson: that's harder in some of these more other than say Huntsville. I mean, I think it would be harder in places like Clarksville and places like that to find good PMs. How have you done that?  [00:03:42] Amy Sylvis: Yeah, we have one property management company that we work with that has scaled with us. So they're outstanding. [00:03:48] Amy Sylvis: Yeah. They have done us. Good. And we have a mutually beneficial relationship there.  [00:03:52] Sam Wilson: Wow. So one that has scaled across all of those assets and all of those various Places you said that you love research, right? Yes. So I'm really curious about what research took you to Evansville, Indiana. it's right on the Ohio River. [00:04:07] Sam Wilson: It's at the bottom of the state, but. I don't know that I've spoken with anyone out of 500 and I don't know where we are when this goes live. We'll be pushing 600 episodes. It's investing in Evansville, Indiana. So  [00:04:17] Amy Sylvis: let's talk about it. Yeah. Yeah. So think Chatanooga 10 years ago. Okay. [00:04:22] Amy Sylvis: Lots of parallels. I know that's a hot take. That's a bold thing to say. Fair, but Evansville is the third largest city in the great state of Indiana. Yep. Indiana sometimes is deemed not as sexy. As maybe some of the Southeast markets, but my goodness is it pro-business. The state government is investing heavily in infrastructure, particularly in Evansville, always a dynamic, really dynamite sign that a market is emerging. [00:04:47] Amy Sylvis: Toyota's bringing a bunch of jobs to the MSA good manufacturing jobs. We're seeing healthcare jobs and hospital expansion there. All of those really great key metrics, as well as decreasing property taxes, which you very rarely hear these days may not stay. But yeah, quite stunning. They've got a state law that property tax can't be more than 2% of the value of the property. [00:05:11] Amy Sylvis: So it's a great environment.  [00:05:13] Sam Wilson: Wow now that's that's. Yeah I are a Hoosier. I wore a Hoosier. I am a Hoosier. Okay. I lived there for 30 years, so I know this state fairly well. But yeah, I mean that so which is, I just surprised, yeah, Evansville that's really intriguing. [00:05:26] Sam Wilson: That's just not something, yes. I would've really thought about, you mentioned the word that the state is, or you mentioned the phrase, the state is heavily investing in infrastructure. What does  [00:05:35] Amy Sylvis: that. Sure. So specifically in the Evansville area, you may be familiar, but there's for the most part, kind of a disjointed disconnected two lane highway going from most of the way from Evansville up to indie, right? [00:05:49] Amy Sylvis: That's changing, they're building an actual freeway building up the li the infrastructure there for logistics, which is another industry that's growing in the great city of Evans. They're redoing the bridge to make it wider and will robust across the river over to Kentucky, making rail lines investing in there and partnering, doing a public private partnership there as well to help with logistics. [00:06:11] Amy Sylvis: So yeah, when the state's willing to invest in doing some of that infrastructure, it's always a good sign.  [00:06:16] Sam Wilson: Yeah, absolutely. No, that's really intriguing. There's a lot of there's a lot of parallels and things that you mentioned between Evansville. And Memphis, except for the fact that the state is investing heavily in infrastructure. [00:06:28] Sam Wilson: I mean, I'm thinking about things like rail lines you're on the water, mean Ohio river for our listeners that aren't familiar with. The Midwest is enormous. It's one of the largest feeders into the Mississippi. So, the, in, in the amount of goods that are transported up and down from grains to goods, I mean, up and down the Ohio is is pretty incredible actually to see. [00:06:47] Sam Wilson: and again, for those of you who aren't listening, that just the fact that they're building a larger bridge, between Indiana and Kentucky is a really it's a really big step, cuz that will actually connect. Now that I think about it, that would then connect really all the way down to Memphis, which is if we get a major highway running through there, that'll be really awesome. [00:07:03] Sam Wilson: So yes very cool. I love that. How, what resources did you use to research this and say, I mean, cause it's one thing to find a newspaper article like, oh whoop you do. They're building a new bridge across the Ohio. We really don't care. No one pays attention, but to aggregate all this data takes time. [00:07:18] Sam Wilson: How did you do  [00:07:19] Amy Sylvis: that? It does yeah, it, it is quite frankly taken quite a bit of time. I've got a massive spreadsheet, I use some VAs to populate it, but you know, really looking at trends from the milk and report that comes out every year to simple things like job growth announced by the bureau of labor statistics. [00:07:36] Amy Sylvis: A amazing resource that is paid, but for me, it's worth it called housing alerts.com. I don't know if you've heard of them. They're mostly single family focused, but as we know. Single family proceeds. Multi-family, it's a leading indicator by about 12 to 18 months. So a lot of great statistics and forecasting by demographers and economists have that site and pump out that data. [00:08:00] Amy Sylvis: So I really look for overall trends, not just, a blip in the radar, but you know, consistent kind of green. In all of those metrics,  [00:08:08] Sam Wilson: is this something you've been kind of, traditionally trained in is in synthesizing this data and then coming up with a conclusion? Cause I think you can throw a lot of data at a lot of us, myself included in this. [00:08:19] Sam Wilson: And I just kinda, I look at it for an hour and I go. What does this tell me I don't even know how to make sense of this. How do you compile all this into something that's meaningful?  [00:08:28] Amy Sylvis: Yeah. So, I think I, to, to answer your question, not overly trained, I do have an MBA. I do have a background in biotech where, data analysis and all of that has been. [00:08:39] Amy Sylvis: Part of, how I've been trained, but nothing specific, but truly understanding where numbers are and how they change over time and being able to just track them and synthesize, Hey, is this getting better or worse? Is this a trend? Is this a blip in the radar? I humbly present to you that it's a bit simpler than maybe it sounds, I think the hardest part is just, compiling the data. [00:09:00] Sam Wilson: Right. Right. And then paint, painting the picture and saying, okay. Yes. Are things moving? What is the general direction that things are moving in that's really, awesome. I love that. Talk to us about what it means to, I guess, have a setback in life. Like what's a setback look like in life for you, and then how have you overcome. [00:09:19] Amy Sylvis: Sure. I love to talk about this just because everyone has setbacks in life, right? None of us gets through this life without a setback or a bump in the road. Right? So it's, not whether you get knocked down, but whether you get back up I was born with cystic fibrosis. Some of you may have heard of this. [00:09:37] Amy Sylvis: It is a genetic disease that impacts about 30,000 people in the us. And when I was born in 1981, my parents were told that I would live to maybe be 12 years. spoiler alert in two weeks, I turned 41 . but growing up there really wasn't much medication or treatment. And I was in and out of the hospital quite a bit with virent lung infections that were resistant to antibiotics. [00:10:00] Amy Sylvis: and it made it really. To attend school regularly. And as I became an adult, hold down a job regularly, because the nature of the illness is progressive deterioration of my lungs in addition to several other organs in my body. So, it. Yeah, there were some bumps in the room there. Happy to dive in with whatever direction you wanna go down. [00:10:22] Sam Wilson: Wow. I guess, where does that bring you today? Some mm-hmm something has either changed medically or medicinally or something where, we get to have this conversation today. Yes.  [00:10:33] Amy Sylvis: well, really scientifically, Explanation until about three years ago as to why I was doing so well. [00:10:39] Amy Sylvis: And what, brought me so far, I say, maybe my hopeful attitude and my faith is how I explain that. But thankfully, a miracle medication did come to the market for the vast majority, not all of people with cystic fibrosis right before the pandemic in November of 2019. And. Almost all of, kind of my struggles. [00:10:58] Amy Sylvis: I'm no longer in and outta the hospital. All of this has virtually disappeared. So, I get to enjoy the great health and live like most people, thankfully. Wow.  [00:11:08] Sam Wilson: Wow. That's gotta be just, I mean, literally life changing. Yes.  [00:11:13] Amy Sylvis: Yeah, it was, there were again, a bump in the road where COVID came and , so I didn't get to fully kind of experience it until quite recently, but. [00:11:21] Amy Sylvis: The true gift of it is this perspective. I knew from a very young age how precious life was that tomorrow wasn't guaranteed. So it was up to me to really take advantage and live life to the fullest and really led me to this career because I wasn't sure how long or if at all, I could trade my time for money. [00:11:40] Amy Sylvis: And that was a big realization where I thought, although I'm sure my parents would've taken care of me, I wanted to be financially independent, not be a burden on them. So, gosh, darn, I'm gonna figure out a way to generate income regardless of my health. So I can continue to pay my bills and live by myself and have a prosperous life. [00:11:57] Amy Sylvis: So, that is really one of the gifts of going through that struggle that has led me to where I am  [00:12:01] Sam Wilson: today. Wow. Wow. That's an incredible perspective. And not one, I think that many of us, would imagine or be able to share if it's like, Hey, I've had a debilitating disease, the bulk of my life, and yet it's been a gift in its own. [00:12:14] Sam Wilson: Right.  [00:12:15] Amy Sylvis: Yeah, that perspective is everything right? Because there truly are. I mean, it's hard when you're going through it, right. I can relate to, maybe people have had other struggles with, family or health or, an inordinate number of things. But, I think it is so important to look back. [00:12:28] Amy Sylvis: Once things do pass as they always do sometimes sooner, sometimes later and see what the gifts are because they're, they are there and they can be utilized as a superpower moving forward in.  [00:12:40] Sam Wilson: Wow. Wow. That's really cool. What did you do before you got into multifamily real estate?  [00:12:46] Amy Sylvis: I was in biotech. [00:12:47] Amy Sylvis: Raise your hand if you're surprised. but the notion that I could be involved in, developing and distributing medications to people that all also suffered, grievous illness was just really fulfilling. And it was a space I was very comfortable in, both personally, but of course, professionally. [00:13:05] Amy Sylvis: So I was there for 13 years doing.  [00:13:06] Sam Wilson: Right, right. Wow. that's absolutely cool. I love that. Let's talk a little bit. Let's take let's thank you for taking the time to really share your sure. Personal health journey and using that as a springboard to say, Hey, look, anything's possible. So, thank you again for being so willing to talk about that. [00:13:22] Sam Wilson: Certainly appreciate it. Of course. Let's go back a little bit. And rewind the tape to the data conversation, a touch, and just kind of caught maybe not so much look in the rear view mirror, but maybe look a little bit out the windshield and say, all right, what do you see? You guys, you're in the multifamily space, right? [00:13:37] Sam Wilson: And it's been crazy hot, been lots of money flooding into it. And we have this potential recession on the horizon. We have inflation that's outta control. People are calling for stagflation, which wouldn't surprise me in the slightest. Where are we going from here? And how are you guys preparing for  [00:13:52] Amy Sylvis: it? I love this question. [00:13:54] Amy Sylvis: Let me get out my crystal ball. thank you.  [00:13:57] Sam Wilson: You're the first person that's ever said. You have one  [00:13:59] Amy Sylvis: it's my superpower. No, you it is all about mitigating risk, right? Because none of us has a crystal ball, but, to your point, there are ways we can hedge ourselves. We can protect our investment, protect our investors contribution to our investments by a going back to market research. There is no one United States real estate market. Right. We all remember 2008 when some markets, I'm in LA completely tanked. [00:14:25] Amy Sylvis: Right. Other markets, some in Texas were like recession, what? Housing Christ, who, right. It really, it was. Almost a non-event it's a great reminder that there are markets in the United States that are so robust and job fr or economically friendly job friendly. All of this. It's not to say, we assume that there won't be issues, but you can really hedge yourself with a recession. [00:14:49] Amy Sylvis: And, being in a market that has recession-resistant industries where we know historically jobs aren't being cut and mentioned Decatur, Alabama. The FBI is expanding thousands of jobs there. The United States space force, which is such a wild thing to say, but that's a real thing is located from Denver to Huntsville. [00:15:09] Amy Sylvis: These are recession resistant jobs. Not to say that there won't be layoffs or pay cuts, but they really position ourselves, to have still great renter demand. But yeah, interest rates are rising for how long? I don't think any of us know, but we do know the fed is really in between a rock and a hard place. [00:15:25] Amy Sylvis: Midterm elections are coming up. The interest on the debt on the national debt is gonna become a little tricky if they raise too much. And we're all familiar with the term, a tape or tantrum, right? The stock market is not happy about this prospect. So in our mind, simply data-wise is looking historically. [00:15:42] Amy Sylvis: It's only a matter of time before the fed starts cutting again, could be two years could be three. But history shows us that's usually the time period from when they fed raises to when cuts start happening again. So right. We are. Yeah, go ahead. That was a bit of a monologue.  [00:15:57] Sam Wilson: I'll take a breath. [00:15:58] Sam Wilson: Oh, I love it. I love it. That's a great way to, that's a great way to frame it, cuz you hear some people, I've been asking this question a lot recently. And some will tell you, how they're buying, right? They'll tell you, changes in their underwriting strategy. They'll tell you changes in, what they're forecasting or how they're, changing the debt they bring on. [00:16:16] Sam Wilson: And for you, you said, Hey, we're not really, you're not really focused on that as much as you are just saying, we're buying in the right locations. And I think, that's a great answer. So I appreciate that.  [00:16:25] Amy Sylvis: Thank you. Yeah, our underwriting, it has definitely changed as well, just to be fully transparent and most of our deals could survive half renters, not paying at all, we're conservative in that respect and always making sure we protect capital, but yeah, the macro economic environment's really fascinating  [00:16:40] Sam Wilson: as. [00:16:41] Sam Wilson: Right, right. Yeah. The macroeconomic is certainly fascinating, but a again, just to reiterate, it's not like the microeconomic environment is what you are more focused on.  [00:16:50] Amy Sylvis: Precisely precisely.  [00:16:51] Sam Wilson: Yeah. Is awesome. Amy, I thank you for coming on today. I certainly appreciate it. Are there any other closing thoughts you would have for our listeners or things you'd like to share before we sign off? [00:16:59] Amy Sylvis: Sure thing. I would just encourage folks as they're on their journey, wherever they are in this journey to know. That obstacles are simply a sign that you're getting closer to your goal. And so keep going on, keep persisting I'm cheering you on. And if you'd like to get in touch with me, would love for you to reach out@silviscapital.com. [00:17:18] Amy Sylvis: If you wanna chat about market research, the economic environment, or investing anything like that I love to talk to people. It's one of the best parts of what I do. So look forward to speaking with. Awesome.  [00:17:28] Sam Wilson: And for those of you who are listening that Silvi capital S Y L V I S. capital.com. Thank you, Amy, for your time today. [00:17:35] Sam Wilson: I appreciate it.  [00:17:36] Amy Sylvis: Appreciate you. Thanks for having me.

On this week's Tech Nation, Moira speaks with the biotech companies at the BIO International Convention in San Diego. They meet in person for the first time in 3 years, where Dr. Gunn was able to speak with Paul Hastings, the Chair of BIO and the President & CEO of Nkarta, about the state of BIO and Nkarta's work on delivering Natural Killer cells for cancer. Joe Panetta, President & CEO of Biocom California, brings insights into California as a whole and its relation globally, as well as the price of drugs. Dr. Richard Austin, founder and CEO of Reglagene talks about choosing their first-in-human drug for the brain cancer, Glioblastoma, and Dr. Chris Nave from Brandon Capital describes Polyactiva's work in the treatment of glaucoma.

Jennifer Caldwell is the Chief Marketing Officer at Aquanomix, with over 25 years of marketing and communications experience. She spent several years in television and media production where she won five Telly Awards and was referenced in a book by the Brookings Institution.Connect with Jennifer on LinkedIn here: https://www.linkedin.com/in/jennifer-a-caldwell-0158205/Connect with the host, Connor Dube, on LinkedIn: https://www.linkedin.com/in/socialsellingexpert/Brought to you by the B2B content marketing experts at www.ProvenContent.comGet access to free content marketing courses, no email opt in required, at www.ProvenContent.com/Free

What happens when you combine an industry-altering, AI-powered platform with a leading CRO's preclinical expertise?  That's what Valo Health and Charles River are answering with the introduction of Logica™. This revolutionary platform aims to accelerate drug discovery and development by finding the most viable molecules faster, helping biotechs and pharma focus their resources only on the ones that will evolve into therapies that patients will receive more quickly.   Join Guido Lanza (Valo) and Julie Frearson (Charles River) as they discuss the components of Logica™, what makes it unique from other platforms, and how it will transform the future of drug discovery.   Show Notes  https://www.criver.com/products-services/discovery-services/logica-transformative-drug-design  https://www.criver.com/insights/charles-river-and-valo-health-launch-logica  https://www.criver.com/eureka/medicine-meet-ai-how-machine-learning-transforming-drug-discovery   Valo Health Is Partnering With Charles River Laboratories To Accelerate Preclinical Drug Discovery   Charles River, Valo Enter AI-enabled Drug Discovery Pact 

While renal disease treatment technologies have seen moderate incremental improvements, there hasn't been a step-change advance in diabetes care since the discovery of insulin more than 100 years ago.  Working with manufacturers of existing diabetes therapeutics in addition to  advancing its own pipeline, Arecor is developing enhanced reformulations of tried-and-true therapeutics like insulin to improve a long-static standard of care. Arecor CEO Sarah Howell, Ph.D. joins the Business of Biotech for a discussion on the company's approach to improving the quality of life for some 200 million insulin-dependent patients worldwide. 

Michael and Vance discuss the state of the U.S. economy, the modern aristocracy, regulatory moats, coercion in gender ideology and the current decline in long term thinking. Michael Vassar is a futurist, activist, and entrepreneur. He is the co-founder and chief science officer of MetaMed Research. Vassar advocates safe development of new technologies for the benefit of humankind. Spencer Greenburg Podcast with Michael: https://clearerthinkingpodcast.com/episode/028LessWrong Thread Michael References: https://www.lesswrong.com/posts/MnFqyPLqbiKL8nSR7/my-experience-at-and-around-miri-and-cfar-inspired-by-zoe#yKo2uuCcwJxbwwyBwJoin the Articulate Ventures Network | https://network.articulate.ventures/ —We are a patchwork of thinkers that want to articulate ideas in a forum where they can be respectfully challenged, improved and celebrated so that we can explore complex subjects, learn from those we disagree with and achieve our personal & professional goals.Book a Legacy Interview | https://legacyinterviews.com/ —A Legacy Interview is a two-hour recorded interview with you and a host that can be watched now and viewed in the future. It is a recording of what you experienced, the lessons you learned and the family values you want passed down. We will interview you or a loved one, capturing the sound of their voice, wisdom and a sense of who they are. These recorded conversations will be private, reserved only for the people that you want to share it with.Contact Vance for a Talk | https://www.vancecrowe.com/ —Vance delivers speeches that reveal important aspects of human communication.  Audiences are entertained, engaged, and leave feeling empowered to change something about the way they are communicating.  Vance tells stories about his own experiences, discusses theories in ways that make them relatable and highlights interesting people, books, and media that the audience can learn even more from. Join the #ATCF Book Club | https://www.vancecrowe.com/book-club

Founder and CEO of the high-performance brand, RéVive Skincare, Dr Gregory Bays Brown and Elana Drell-Szyfer have shaped the brand into one of the most advanced of its kind today.With Dr Brown's expertise in plastic and reconstructive surgery and Elana's background of senior leadership at the world's largest beauty corporations, RéVive showcases a combined 50 years of scientific innovation in an ever-evolving beauty landscape. If you enjoyed this episode, please make sure you like, subscribe and share with anyone you know who will love it too!Founded Beauty is available on all podcast platforms and we release new episodes every Monday and Thursday so be sure to follow the podcast to be notified. We really appreciate every single listen, share, and review. It goes such a long way and helps us reach new listeners. Follow Akash & RéVive Skincare:Akash Mehta: @mehta_aFable & Mane: @fableandmanewww.fableandmane.comRéVive Skincare: @reviveskincarewww.reviveskincare.comFor more information about Founded Beauty, please visit www.foundedbeauty.com#foundedbeauty See acast.com/privacy for privacy and opt-out information.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Allan Shaw, Consulting CFO, Special Advisor & Board Member of several biotech companies. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Allan, covering: The sensitive cash position of biotech's as a ‘hangover' after a decade of partying as the market was high. The potential domino effect and collateral impact of the biotech capital slowdown on the supply chain ecosystem. Core commonalities between biotech's of all shapes and sizes, and what challenges they face today. How CRO/CDMO and other pharma services' vendors can add the most value during an expected bumpy ride for biotech's. Allan is a senior biopharmaceutical executive and board member with 20+ years of international and transactional experience. He is a five-time public company CFO and has served on six public boards, which included the chairing of two audit and two compensation committees. He is currently involved with a portfolio of healthcare activities, including serving as Portage Biotech's Chief Financial Officer. Prior, Shaw also served as managing director and life science practice leader for Alvarez & Marsal's healthcare industry group. He was also CFO at Serono. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Join Investor's Business Daily senior markets writer Ken Shreve and Alissa Coram, IBD's multimedia content editor, as they discuss how to uncover potential market leaders in the massive biotech industry group and how to find proper entries for biotech ETFs to capitalize on this emerging trend. 

Can CRISPR edit out a heart attack? What happens on #GutTok? And is health care recession-proof? Sek Kathiresan, cardiologist and CEO of Verve Therapeutics, joins us to explain the company's work on preventing heart disease with genome editing. Then, STAT's Isabella Cueto joins us to discuss "Hot girls have IBS," an internet in-joke that evolved into a movement for people with chronic illness. We also break down the latest news in the life sciences, including a long-awaited victory for Novavax and ostensible good news for biotech.

Nick talks to medicinal chemist Sam Banister, who is co-founder and Chief Science Officer at Psylo, a biotech startup focused on developing next-generation psychedelic medicines. They discuss: the past, present, and future of psychedelic science; Sam's journey from academia to biotech startup co-founder; Alexander Shulgin; psychedelics like psilocybin, DMT, and others; and psychedelics & society. USEFUL LINKSSign up for the weekly Mind & Matter newsletter[https://mindandmatter.substack.com/?sort=top]Follow Nick's work through Linktree:[https://linktr.ee/trikomes]DoubleBlind Magazine, a leading source of news, information, and education about psychedelics. Use code MINDMATTER for 20% site-wide.[https://www.doubleblindmag.com/mindmatter]Athletic Greens, comprehensive daily nutrition (Free 1-year supply Vitamin D w/ purchase)[https://www.athleticgreens.com/mindandmatter]Organize your digital highlights & notes w/ Readwise (2 months free w/ sub)[https://readwise.io/nickjikomes/]Learn more about our podcast sponsor, Dosist[https://dosist.com]Support the show

Andrew Barnell is the CEO of Geneoscopy, a life sciences company he co-founded with his sister to develop diagnostic tests for gastrointestinal health. The company recently raised $105 million and was ranked the 5th-largest biotech or agtech firm in St. Louis. Andrew talks about the formation of the business, operating a company with family, fundraising and how they'll use their latest round of capital.

TODAY'S SPONSOR:GOOD IDEA is new favorite blood sugar-stabilizing sparkling water that combines a blend of amino acids, chromium and electrolytes to help reduce the blood sugar responses at meals. I love having one in my car or bringing one with me to events and social gatherings where I can't control the menu or I know I'm going to eat something with carbs.(Much tastier, more portable and socially acceptable than Apple Cider Vinegar!

Franck Mouton, président de France Biotech, était l'invité de Christophe Jakubyszyn dans Good Morning Business, ce mardi 12 juillet. Ils se sont penchés sur les défis que doit relever la France dans le secteur stratégique de l'innovation en santé, sur BFM Business. Retrouvez l'émission du lundi au vendredi et réécoutez la en podcast.

There's quite literally nothing about health and wellness that won't be utterly transformed by the power of AI. The Future You: How Artificial Intelligence (AI) Can Help You Get Healthier, Stress Less, and Live Longer explores how AI is disrupting healthcare and what you need to know to navigate the new medical paradigm and improve your health in monumental ways—starting today. There's quite literally nothing about health and wellness that won't be utterly transformed by the power of AI. The Future You will show you what's coming—and what is already here.Biotech expert and author Harry Glorikian helps readers understand how to use technology (that they very likely already have) to create personalized healthcare experiences.Harry Glorikian is a global business expert, healthcare entrepreneur, podcaster, and author. For over three decades, he has built a breadth of successful ventures in the healthcare space, and he is well known for being at the forefront of helping invest in and grow innovative healthcare companies that are tackling groundbreaking areas of healthcare and biotechnology. He currently serves as a General Partner at Scientia Ventures, a VC firm focused on up-leveling companies that have the potential to transform healthcare.

Lisa Bowers is a mission-driven, visionary, senior executive in the biopharmaceutical industry. She has extensive experience leading strategic, operational, field, program and product initiatives in healthcare. She is passionate about improving access to healthcare and healthcare products for underserved populations in businesses and nonprofits. Lisa has an Master of Health Services Administration and a bachelor's degree in English.Episode NotesWith the overturning of Roe v. Wade on June 24, 2022 women's rights were grievously attacked. Lisa brings a long history of working in biotech and reproductive health. Lisa shares her perspectives on what the overturning of Roe means to women and their reproductive health. She brings an optimistic viewpoint to the discussion and shares how this may be a catalyst for much needed change to contraception and women's health care.While a lot of the discussion focuses on reproductive health, we also talk about the work she currently does at Day One Biopharmaceuticals where she focuses on bringing cancer treatments to children with brain cancer. Typically, most biotech companies study their medicines in adults first and then move to children later, but Day One begins their drug development programs in children first. We also talk about the important role of humanities and communications in STEM. Music used in the podcast: Higher Up, Silverman Sound StudioAcronyms, Definitions, and Fact CheckDay One BioPharmaceuticals - https://www.dayonebio.comPediatric low-grade gliomas are a heterogeneous set of tumors. They encompass tumors of astrocytic, oligodendroglial, and mixed glial-neuronal histology. Although their clinical behavior can vary, the majority of low-grade gliomas are indolent and do not undergo malignant transformation. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917804/)Shelley Alpern, Director of Corporate Engagement at Rhia Ventures1 in 8 pregnancies end in miscarriage. 1 in 5 pregnancies end in abortion."Reproductive Justice" by Loretta Ross - https://www.amazon.com/Reproductive-Justice-Introduction-Vision-Century/dp/0520288203Rhia Ventures - https://rhiaventures.orgSisterSong - SisterSong is a Southern based, national membership organization; our purpose is to build an effective network of individuals and organizations to improve institutional policies and systems that impact the reproductive lives of marginalized communities. (https://www.sistersong.net)Planned Parenthood Mar Monte - Planned Parenthood Mar Monte (PPMM) is the largest Planned Parenthood affiliate in the U.S., providing medical and education services to more than 220,000 people annually at over 30 health center locations in mid-California and northern Nevada. (https://www.plannedparenthood.org/planned-parenthood-mar-monte)National Network of Abortion Funds - The National Network of Abortion Funds builds power with members to remove financial and logistical barriers to abortion access by centering people who have abortions and organizing at the intersections of racial, economic, and reproductive justice. (https://abortionfunds.org)Additional podcast notes can be found at https://ordinarily-extraordinary.com/episode-86-lisa-bowers/

Sharoz Khalid is an electrical engineer and citizen of Pakistan. In this interview, Vance and Sharoz discuss the outcomes of inflation in his country and how the United State's fiscal policy effects countries like Pakistan. They also discuss mob behavior and foreign political systems. #pakistan #inflation #foreignpolicy Join the Articulate Ventures Network | https://network.articulate.ventures/ —We are a patchwork of thinkers that want to articulate ideas in a forum where they can be respectfully challenged, improved and celebrated so that we can explore complex subjects, learn from those we disagree with and achieve our personal & professional goals.Book a Legacy Interview | https://legacyinterviews.com/ —A Legacy Interview is a two-hour recorded interview with you and a host that can be watched now and viewed in the future. It is a recording of what you experienced, the lessons you learned and the family values you want passed down. We will interview you or a loved one, capturing the sound of their voice, wisdom and a sense of who they are. These recorded conversations will be private, reserved only for the people that you want to share it with.Contact Vance for a Talk | https://www.vancecrowe.com/ —Vance delivers speeches that reveal important aspects of human communication.  Audiences are entertained, engaged, and leave feeling empowered to change something about the way they are communicating.  Vance tells stories about his own experiences, discusses theories in ways that make them relatable and highlights interesting people, books, and media that the audience can learn even more from. Join the #ATCF Book Club | https://www.vancecrowe.com/book-club

Serial inventor and entrepreneur Alex Blyth had long held interests in health and science, but losing his mom to pancreatic cancer was the inflection point that launched LIfT Biosciences in 2016. Now, the preclinical company is on a mission to develop the world's first 'off-the-shelf' cell therapy to destroy all solid tumors, irrespective of strain or mutation, beginning with pancreatic cancer. On this episode of the Business of Biotech, Blyth shares the company's scientific approach and progress, and we explore the shortcomings of legacy clinical protocols including the inherent problems and limitations of mouse models.